JP2014510064A - Ｎｒｆ２活性剤としてのカルコン誘導体 - Google Patents

Ｎｒｆ２活性剤としてのカルコン誘導体 Download PDF

Info

Publication number
JP2014510064A
JP2014510064A JP2013555631A JP2013555631A JP2014510064A JP 2014510064 A JP2014510064 A JP 2014510064A JP 2013555631 A JP2013555631 A JP 2013555631A JP 2013555631 A JP2013555631 A JP 2013555631A JP 2014510064 A JP2014510064 A JP 2014510064A
Authority
JP
Japan
Prior art keywords
disease
compound
nrf2
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013555631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510064A5 (enExample
Inventor
ビスワル，シャーム
シムラッパ，ラジェシュ
クマール，サルベッシュ
マルホトラ，サンジャイ，ヴイ．
クマール，ヴィニット
ジョン−ヒュン，キム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2014510064A publication Critical patent/JP2014510064A/ja
Publication of JP2014510064A5 publication Critical patent/JP2014510064A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
JP2013555631A 2011-02-25 2012-02-27 Ｎｒｆ２活性剤としてのカルコン誘導体 Pending JP2014510064A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446716P 2011-02-25 2011-02-25
US61/446,716 2011-02-25
US201161500272P 2011-06-23 2011-06-23
US61/500,272 2011-06-23
PCT/US2012/026744 WO2012116362A2 (en) 2011-02-25 2012-02-27 Chalcone derivatives as nrf2 activators

Publications (2)

Publication Number Publication Date
JP2014510064A true JP2014510064A (ja) 2014-04-24
JP2014510064A5 JP2014510064A5 (enExample) 2015-04-16

Family

ID=46721498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555631A Pending JP2014510064A (ja) 2011-02-25 2012-02-27 Ｎｒｆ２活性剤としてのカルコン誘導体

Country Status (6)

Country Link
US (1) US20140088052A1 (enExample)
EP (1) EP2678305A4 (enExample)
JP (1) JP2014510064A (enExample)
AU (1) AU2012222074A1 (enExample)
CA (1) CA2827990A1 (enExample)
WO (1) WO2012116362A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534667A (ja) * 2014-11-19 2017-11-24 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． フマル酸ジメチルを含む医薬マトリクス製剤
JP2020503332A (ja) * 2016-12-27 2020-01-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｎｒｆ２活性化物質
JP2024503610A (ja) * 2021-01-07 2024-01-26 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム アナタビンを含む組成物およびその使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071945B2 (en) 2011-06-15 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2015187934A1 (en) * 2014-06-06 2015-12-10 Cureveda, Llc Functionalized hetroaryl enones exhibiting nrf2 activation and their method of use
ES2570452B1 (es) * 2014-10-15 2017-04-19 Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
WO2016153432A1 (en) * 2015-03-23 2016-09-29 Nanyang Polytechnic Drugs from substituted phenyl cinnamyl ketones
US10822299B2 (en) * 2016-05-26 2020-11-03 The Regents Of The University Of California Compounds and methods for hematopoietic regeneration
CN107056707B (zh) * 2017-01-23 2019-08-23 温州医科大学 一种3,4,5-三甲氧基苯类化合物及其在制备抗氧化药物中的应用
MX2021002060A (es) 2018-08-20 2021-07-21 Janssen Pharmaceutica Nv Inhibidores de la interacción proteína-proteína keap1-nrf2.
WO2020094767A1 (en) * 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of nrf2 activators for the treatment of staphylococcus aureus infections
CN111792990A (zh) * 2019-04-09 2020-10-20 中国科学院上海药物研究所 一种不饱和酮类化合物、其制备方法和用途
CA3171430A1 (en) * 2020-03-13 2021-09-16 Brent R. Stockwell Gpx4 compounds and compositions and methods of treatment using same
MX2024000806A (es) * 2021-07-15 2024-04-15 Allspim Composiciones y métodos para prevenir y/o tratar enfermedades asociadas con la expresión de la interleuquina 23 (il-23).
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
CN115572255A (zh) * 2022-04-29 2023-01-06 无锡捷化医药科技有限公司 一种查尔酮类化合物的制备方法
CN115433073B (zh) * 2022-08-15 2024-04-19 兰州大学 一种卡瓦胡椒素b类似物的制备方法及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6323136A (ja) * 1986-03-14 1988-01-30 Seizo Miyata 非線形光学素子
JPH02178249A (ja) * 1988-12-28 1990-07-11 Mitsubishi Kasei Corp 光学活性ケトンの製造法
WO2000018390A1 (fr) * 1998-09-28 2000-04-06 Hsp Research Institute, Inc. Inducteurs d'expression de proteine de choc thermique
US20030065039A1 (en) * 1997-06-26 2003-04-03 Statens Serum Institute Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
WO2003033662A2 (en) * 2001-10-16 2003-04-24 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239447T1 (de) * 1997-09-29 2003-05-15 Inhale Therapeutic Syst In verneblern verwendbare, stabilisierte zubereitungen
KR100830541B1 (ko) * 2006-08-11 2008-05-21 충남대학교산학협력단 인터루킨-5 저해효과를 갖는 신규 찰콘계 유도체

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6323136A (ja) * 1986-03-14 1988-01-30 Seizo Miyata 非線形光学素子
JPH02178249A (ja) * 1988-12-28 1990-07-11 Mitsubishi Kasei Corp 光学活性ケトンの製造法
US20030065039A1 (en) * 1997-06-26 2003-04-03 Statens Serum Institute Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
WO2000018390A1 (fr) * 1998-09-28 2000-04-06 Hsp Research Institute, Inc. Inducteurs d'expression de proteine de choc thermique
WO2003033662A2 (en) * 2001-10-16 2003-04-24 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
CENINI, S. ET AL.: "Intramolecular amination catalyzed by ruthenium and palladium. Synthesis of 2-acyl indoles and 2-ary", JOURNAL OF MOLECULAR CATALYSIS A: CHEMICAL, vol. 111(1-2), JPN6015041097, 1996, pages 37 - 41, ISSN: 0003173890 *
CHIARADIA, LOUISE DOMENEGHINI ET AL.: "Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 16(2), JPN6015041086, 2008, pages 658 - 667, ISSN: 0003173882 *
DENG, JINXIA ET AL.: "Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 15(14), JPN6015041091, 2007, pages 4985 - 5002, ISSN: 0003173886 *
DESENKO, S. M. ET AL.: "Fluorine-containing dihydro derivatives of 1,2,4-triazolo[1,5-a]pyrimidine", DOPOVIDI AKADEMII NAUK UKRAINI, vol. (8), JPN7015002828, 1993, pages 122 - 125, ISSN: 0003173889 *
EDWARDS, MICHAEL L. ET AL.: "Chalcones: A New Class of Antimitotic Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33(7), JPN6015041088, 1990, pages 1948 - 1954, ISSN: 0003173884 *
HAS, CHANDRA ET AL.: "Studies in Heterocyclic Compounds. Part XLII. Synthesis and Antibacterial Activity of some New 1,3-D", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 73(11), JPN6015041106, 1996, pages 614 - 615, ISSN: 0003173896 *
HENMI, KAYO ET AL.: "Methoxy- and Fluoro-chalcone Derivatives Arrest Cell Cycle Progression and Induce Apoptosis in Human", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 32(6), JPN6015041087, 2009, pages 1109 - 1113, XP055122690, ISSN: 0003173883, DOI: 10.1248/bpb.32.1109 *
KANKANALA, KAVITHA ET AL.: "A New and Direct Synthesis of Chalcones Via TFAA-H3PO4 Mediated C-C Bond Forming Reaction", LETTERS IN ORGANIC CHEMISTRY, vol. 8(1), JPN6015041103, 2011, pages 53 - 59, ISSN: 0003173894 *
KAU, TWEENY R. ET AL.: "A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcript", CANCER CELL, vol. 4(6), JPN6015041095, 2003, pages 463 - 476, ISSN: 0003173888 *
LI, ZHENG-XIANG ET AL.: "Synthesis of a New Series of Chalcone Derivatives and Their Antifungal Activities", JOURNAL OF CHINESE PHARMACEUTICAL SCIENCES, vol. 13(4), JPN6015041090, 2004, pages 245 - 248, ISSN: 0003173885 *
MEHRA, HARI SHANKER ET AL.: "Condensation of aryldiazonium salts with reactive unsaturated compounds. Part VIII. Action of aryldi", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 33, JPN6015041100, 1956, pages 618 - 20, ISSN: 0003173892 *
MULCHANDANI, NEWAND B. ET AL.: "Synthesis of chalcones derived from quinacetophenone and its methyl ethers", CHEMISCHE BERICHTE, vol. 93, JPN7015002829, 1960, pages 1918 - 1924, ISSN: 0003173897 *
NARENDER, T. ET AL.: "A simple and highly efficient method for the synthesis of chalcones by using borontrifluoride-ethera", TETRAHEDRON LETTERS, vol. 48(18), JPN6015041099, 2007, pages 3177 - 3180, ISSN: 0003173891 *
PATTI, ANGELA ET AL.: "Hydrogenation of ortho-nitrochalcones over Pd/C as a simple access to 2-substituted 1,2,3,4-tetrahyd", TETRAHEDRON, vol. 66(30), JPN6015041101, 2010, pages 5607 - 5611, ISSN: 0003173893 *
QUINTIN, JEROME ET AL.: "Synthesis and biological evaluation of a series of tangeretin-derived chalcones", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19(1), JPN6015041093, 2009, pages 167 - 169, ISSN: 0003173887 *
TULLY, WARREN ET AL.: "Preparation of cyclomanganated chalcones and their reactions with methyl acrylate and other α,β-un", JOURNAL OF ORGANOMETALLIC CHEMISTRY, vol. 503(1), JPN6015041109, 1995, pages 75 - 92, ISSN: 0003173898 *
WANG, HONGSHE ET AL.: "Iodine-catalyzed efficient synthesis of chalcones by grinding under solvent-free conditions", CANADIAN JOURNAL OF CHEMISTRY, vol. 87(9), JPN6015041105, 2009, pages 1209 - 1212, ISSN: 0003173895 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534667A (ja) * 2014-11-19 2017-11-24 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． フマル酸ジメチルを含む医薬マトリクス製剤
JP2020503332A (ja) * 2016-12-27 2020-01-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｎｒｆ２活性化物質
JP7088933B2 (ja) 2016-12-27 2022-06-21 バイオジェン・エムエイ・インコーポレイテッド Ｎｒｆ２活性化物質
JP2024503610A (ja) * 2021-01-07 2024-01-26 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム アナタビンを含む組成物およびその使用

Also Published As

Publication number Publication date
AU2012222074A1 (en) 2013-09-12
WO2012116362A2 (en) 2012-08-30
WO2012116362A3 (en) 2012-11-29
EP2678305A2 (en) 2014-01-01
EP2678305A4 (en) 2015-11-04
US20140088052A1 (en) 2014-03-27
CA2827990A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
JP2014510064A (ja) Ｎｒｆ２活性剤としてのカルコン誘導体
Lu et al. Cellular mitophagy: mechanism, roles in diseases and small molecule pharmacological regulation
CN109640967B (zh) 抑制胆碱向三甲胺(tma)的转化的方法
US20220001014A1 (en) Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
Mokry et al. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs
Chen et al. Carbon monoxide ameliorates acetaminophen‐induced liver injury by increasing hepatic HO‐1 and Parkin expression
CN108309982B (zh) 3位取代的5H-[1,2,4]三嗪[5,6-b]吲哚衍生物的用途
TW202304496A (zh) 柳樹萃取物及其於治療病毒感染、過敏反應及其他醫療病況之用途
CN103561732A (zh) 治疗化合物
US20160008336A1 (en) Hdac inhibitors for the treatment of traumatic brain injury
WO2020094767A1 (en) Use of nrf2 activators for the treatment of staphylococcus aureus infections
JP2017520620A (ja) 放射線および化学損傷に対する保護のためのセコイソラリシレジノールジグルコシド（ｓｄｇ）および関連化合物の使用
CN115209908A (zh) 具有神经保护、免疫调节、抗炎和抗微生物活性的基于蛋白质的药学组合物
TW200410690A (en) Topical treatment of skin diseases
JP2007529494A (ja) がんに対する予防薬および治療薬として単独投与およびフェンレチニドと併用される４−オキソ−フェンレチニド
CN104958286B (zh) 用于治疗疾病的化合物
JP2008514733A (ja) 標的化プロテアーゼインヒビターによる、外傷性もしくは変性性の神経疾患、耳科疾患または眼科疾患の処置
US20230372311A1 (en) Compositions and methods of treating age-related retinal dysfunction
Wang et al. Cyclooxygenase-1 deletion in 5× FAD mice protects against microglia-induced neuroinflammation and mitigates cognitive impairment
US20210169850A1 (en) Indoline derivatives, compositions comprising them and uses thereof
CN111163765A (zh) 用于抑制胆碱向三甲胺(tma)的转化的方法
CN117396505A (zh) 治疗炎症的方法
Rashed et al. Modulation of sirtuin-1, apoptosis and redox signaling pathways by astringenin: a potential Parkinsonism therapeutic effect
Davies New therapeutic approaches for cystic fibrosis lung disease
US20230310542A1 (en) Epigenetic modifiers to treat retinal degenerations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160621